Women with PMOS should get subsidised weight-loss drugs, Australian advocates say
With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label Get our breaking news email , free app or daily news podcast Women living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.
Continue reading...
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.theguardian.com — the content belongs to The Guardian Australia - World.
